

# Medical Drugs Excluded At Launch List

Effective May 8, 2024



This list contains provider-administered drugs that are newly approved by the Food and Drug Administration (FDA). Drugs on this list are being evaluated by PreferredOne for safety, efficacy, and coverage consideration. Completion of review and decision of coverage will be made within 12 months of FDA approval. Prior to review and decision, these medications will not be covered. For more information, see Pharmacy Policy PP/R001 – Review of New FDA-Approved Drugs and Clinical Indications.

DRUG TRADE NAME	TARGET INDICATION	FDA APPROVAL	REMOVAL FROM LIST
<b>Vyjuvek</b> (beremagene geperpavec-svdt)	treatment of wounds in patients 6 months of age and older with dystrophic epidermolysis bullosa with mutation(s) in the collagen type VII alpha 1 chain (COL7A1) gene.	05/19/2023	05/19/2024
<b>Columvi</b> (glofitamab-gxbm)	for relapsed or refractory diffuse large B-cell lymphoma, not otherwise specified (DLBCL, NOS) or large B-cell lymphoma (LBCL) arising from follicular lymphoma, after two or more lines of systemic therapy.	6/15/2023	6/15/2024
<b>Vyvgart Hytrulo</b> (efgartigimod alfa and hyaluronidase-qvfc), subcutaneous injection	Treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive	6/20/2023	6/20/2024
<b>Elevidys</b> (delandistrogene moxeparvovec-rokl)	Treatment of ambulatory pediatric patients aged 4 through 5 years with Duchenne muscular dystrophy (DMD) with a confirmed mutation in the DMD gene.	6/22/2023	6/22/2024
<b>Rystiggo</b> (rozanolixizumab-noli)	Treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) or antimuscle-specific tyrosine kinase (MuSK) antibody positive	6/27/2023	6/27/2024
<b>Roctavian</b> (valoctocogene roxaparvovec-rvox)	Treatment of adults with severe hemophilia A (congenital factor VIII (FVIII) deficiency with FVIII activity < 1 IU/dL) without antibodies to adeno-associated virus serotype 5 (AAV5) detected by an FDA-approved test	6/29/2023	6/29/2024
<b>Vanflyta</b> (quizartinib)	Treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) that is FLT3-ITD positive as detected by an FDA-approved test	7/20/2023	7/20/2024
<b>Izervay</b> (avacincaptad pegol intravitreal solution)	Treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD)	8/4/2023	8/4/2024
<b>Talvey</b> (talquetamab-tgvs)	Treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody	8/9/2023	8/9/2024

DRUG TRADE NAME	TARGET INDICATION	FDA APPROVAL	REMOVAL FROM LIST
<b>Elrexio</b> (elranatamab-bcmm)	Treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody	8/14/2023	8/14/2024
<b>Daxxify</b> (daxibotulinumtoxinA-lanm)	Treatment of cervical dystonia in adult patients	8/14/2023	8/14/2024
<b>Hepzato Kit</b> (melphalan/hepatic delivery system)	A liver-directed treatment for adult patients with uveal melanoma with unresectable hepatic metastases affecting less than 50% of the liver and no extrahepatic disease or extrahepatic disease limited to the bone, lymph nodes, subcutaneous tissues, or lung that is amenable to resection or radiation	8/14/2023	8/14/2024
<b>Veopoz</b> (pozelimab-bbfg)	Treatment of adult and pediatric patients 1 year of age and older with CD55-deficient protein-losing enteropathy (PLE), also known as CHAPLE disease	8/18/2023	8/18/2024
<b>Eylea HD</b> (aflibercept)	Treatment of Neovascular (Wet) age-related macular degeneration; Diabetic macular edema; and Diabetic retinopathy	8/18/2023	8/18/2024
<b>Tyruko</b> (natalizumab-szin)	Indicated as monotherapy for the treatment of relapsing forms of multiple sclerosis, to include clinically isolated syndrome, relapsingremitting disease, and active secondary progressive disease, in adults	8/25/2023	8/25/2024
<b>Rivfloza</b> (nedosiran)	Treatment to lower urinary oxalate levels in children 9 years of age and older and adults with primary hyperoxaluria type 1 (PH1) and relatively preserved kidney function	9/29/2023	9/29/2024
<b>Tofidence</b> (tocilizumab-bavi)	Treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (DMARDs); patients 2 years of age and older with active polyarticular juvenile idiopathic arthritis (PJIA); patients 2 years of age and older with active systemic juvenile idiopathic arthritis (SJIA)	9/29/2023	9/29/2024
<b>Cosentyx</b> (secukinumab) IV formulation	Treatment of adults with psoriatic arthritis (PsA), ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA)	10/06/2023	10/06/2024

DRUG TRADE NAME	TARGET INDICATION	FDA APPROVAL	REMOVAL FROM LIST
<b>Zilbrysq</b> (zilucoplan)	Treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive	10/17/2023	10/17/2024
<b>Zymfentra</b> (infliximab-dyyb)	Maintenance treatment of moderately to severely active ulcerative colitis following treatment with an infliximab product administered intravenously; moderately to severely active Crohn's disease following treatment with an infliximab product administered IV	10/23/2023	10/23/2024
<b>Loqtorzi</b> (toripalimab-tpzi)	In combination with cisplatin and gemcitabine, for the first-line treatment of adults with metastatic or with recurrent, locally advanced nasopharyngeal carcinoma (NPC). As a single agent, for the treatment of adults with recurrent unresectable or metastatic NPC with disease progression on or after a platinum-containing chemotherapy.	10/27/2023	10/27/2024
<b>Wezlana</b> (ustekinumab-auub)	Patients 6 years and older with moderate to severe plaque psoriasis (PsO), who are candidates for phototherapy or systemic therapy. Patients 6 years and older with active psoriatic arthritis (PsA). Adult patients with moderately to severely active Crohn's disease (CD), and adult patients with moderately to severely active ulcerative colitis (UC).	10/31/2023	10/31/2024
<b>Fruzaqla</b> (fruquintinib)	Treatment of adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-vascular endothelial growth factor (VEGF) therapy, and, if RAS wild-type and medically appropriate, an anti-epidermal growth factor receptor (EGFR) therapy.	11/8/2023	11/8/2024
<b>Adzynma</b> (ADAMTS13, recombinant-krhn)	Prophylactic or on demand enzyme replacement therapy (ERT) in adult and pediatric patients with congenital thrombotic thrombocytopenic purpura (cTTP)	11/9/2023	11/9/2024
<b>Ryzneuta</b> (efbemalenograstim alfa-vuxw)	To decrease the incidence of infection, as manifested by febrile neutropenia, in adult patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.	11/16/2023	11/16/2024
<b>Avzivi</b> (bevacizumab-tjnj)	Treatment of patients with unresectable or metastatic hepatocellular carcinoma (HCC) who have not received prior systemic therapy.	12/06/2023	12/06/2024
<b>Casgevy</b> (exagamglogene autotemcel)	Treatment of SCD in patients 12 years and older with recurrent vaso-occlusive crises (VOCs).	12/08/2023	12/08/2024

DRUG TRADE NAME	TARGET INDICATION	FDA APPROVAL	REMOVAL FROM LIST
<b>Lyfgenia</b> (lovotibeglogene autotemcel)	Treatment of SCD in patients 12 years and older with a history of vaso-occlusive events (VOEs).	12/08/2023	12/08/2024
<b>Alyglo</b> (immune globulin intravenous, human-stwk)	Treatment of primary humoral immunodeficiency in adults.	12/17/2023	12/17/2024
<b>Udenyca Onbody</b> (pegfilgrastim-cbqv)	Decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.	12/26/2023	12/26/2024
<b>Casgevy</b> (exagamglogene autotemcel)	Treatment of patients aged 12 years and older with transfusion-dependent $\beta$ -thalassemia	01/17/2024	01/17/2025
<b>Aurlumyn</b> (iloprost)	Treatment of severe frostbite in adults to reduce the risk of digit amputations.	02/15/2024	02/15/2025
<b>Amtagvi</b> (lifileucel)	Treatment of adult patients with unresectable or metastatic melanoma previously treated with a PD-1 blocking antibody, and if BRAF V600 mutation positive, a BRAF inhibitor with or without a MEK inhibitor.	02/16/2024	02/16/2025
<b>Exblifep</b> (cefepime/enmetazobactam)	Treatment of patients 18 years of age and older with complicated urinary tract infections including pyelonephritis, caused by the following susceptible microorganisms: Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Proteus mirabilis, and Enterobacter cloacae complex.	02/23/2024	02/23/2025
<b>Letybo</b> (letibotulinumtoxinA-wlbg)	temporary improvement in the appearance of moderate to severe glabellar (frown) lines associated with corrugator and/or procerus muscle activity in adult patients	03/04/2024	03/04/2025
<b>Jubbonti</b> (denosumab-bbdz)	Treatment of postmenopausal women with osteoporosis at high risk for fracture. Treatment to increase bone mass in men with osteoporosis at high risk for fracture. Treatment of glucocorticoid-induced osteoporosis in men and women at high risk for fracture. Treatment to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer. Treatment to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer.	03/05/2024	03/05/2025

DRUG TRADE NAME	TARGET INDICATION	FDA APPROVAL	REMOVAL FROM LIST
<b>Wyost</b> (denosumab-bbdz)	Prevention of skeletal-related events in patients with multiple myeloma and in patients with bone metastases from solid tumors. Treatment of adults and skeletally mature adolescents with giant cell tumor of bone that is unresectable or where surgical resection is likely to result in severe morbidity. Treatment of hypercalcemia of malignancy refractory to bisphosphonate therapy	03/05/2024	03/05/2025
<b>Tyenne</b> (tocilizumab-aazg)	Treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs. Treatment of active polyarticular juvenile idiopathic arthritis (PJIA) in patients 2 years of age and older. Treatment of active systemic juvenile idiopathic arthritis (SJIA) in patients 2 years of age and older.	03/06/2024	03/06/2025
<b>Lenmeldy</b> (atidarsagene autotemcel)	Treatment of children with pre-symptomatic late infantile, presymptomatic early juvenile or early symptomatic early juvenile metachromatic leukodystrophy.	03/18/2024	03/18/2025
<b>Vafseo</b> (vadadustat)	Treatment of anemia due to chronic kidney disease (CKD) in adults who have been receiving dialysis for at least three months.	3/27/2024	3/27/2025
<b>Anktiva</b> (nogapendekin alfa inbakicept-pmln)	Treatment of adult patients with BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ with or without papillary tumors.	04/22/2024	04/22/2025
<b>Beqvez</b> (fidanacogene elaparvovec-dzkt)	Treatment of adults with moderate to severe hemophilia B (congenital factor IX deficiency) who currently use factor IX prophylaxis therapy, or have current or historical life-threatening hemorrhage, or have repeated, serious spontaneous bleeding episodes, and, do not have neutralizing antibodies to adeno-associated virus serotype Rh74var capsid as detected by an FDA-approved test.	04/26/2024	04/26/2025
<b>Hercessi</b> (trastuzumab-strf)	Indicated for adjuvant breast cancer treatment and metastatic breast cancer.	04/29/2024	04/29/2025